This label expansion adds a new revenue driver for HUTCHMED's partnered asset; watch for NRDL inclusion for this indication to accelerate volume. The existing commercial infrastructure via AstraZeneca and prior NRDL listing for lung cancer de-risks launch execution. Monitor upcoming quarterly results for initial prescription trends.
Drug in focus
HCM drug pipeline →ORPATHYS
◆ Mixed Named in this 6-K- Impact
- Phase
- Approved in China (3 indications); global Phase 3 readout pending
- Time to market
- Already approved and marketed in China (lung cancer since 2021, gastric cancer July 2026). Ex-China (US/EU) approval is not filed yet — timing hinges on the SAFFRON global Phase 3 readout expected H2 2026.
- Next catalyst
- None dated
What to watchWatch for SAFFRON/SANOVO Phase 3 topline data in H2 2026, a positive readout supports global (ex-China) filings for savolitinib and would be the biggest near-term share-price lever; a miss or delay would hit a stock already near its 52-week low ($11.13 vs $18.30 high). HUTCHMED carries $1.37B cash, so the stock isn't a financing story, but this one drug's readout is the dominant H2 catalyst alongside sovleplenib NDA decisions.
How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jul 2 $11.44entry
- T+1 · 4mo ago +1.84%α +0.96% · $11.65
- T+5 · 4mo ago −4.02%α −4.95% · $10.98
- T+20 · 4mo ago −5.86%α −5.44% · $10.77
- T+60 · 7w ago +21.50%α +18.50% · $13.90
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
HUTCHMED (HCM) announces conditional NMPA approval in China for ORPATHYS (savolitinib) to treat MET-amplified advanced gastric or gastroesophageal junction adenocarcinoma in patients who have failed at least two prior systemic treatments. This is the third approved indication for ORPATHYS in China, supported by a pivotal Phase II study showing a 32.3% objective response rate, and the drug is already on the National Reimbursement Drug List for its prior lung cancer indication, providing a clear commercial path alongside partner AstraZeneca.
Key Facts
- ORPATHYS (savolitinib) received conditional NMPA approval for MET-amplified advanced GC/GEJ adenocarcinoma after >=2 prior systemic treatments
- Approval supported by Phase II study (NCT04923932): IRC-assessed ORR 32.3% (95%CI: 21.2%-45.1%), DCR 63.1%, median DoR 9.7 months, median PFS 4.0 months
- Estimated annual incidence of MET-amplified gastric cancer in China is ~18,000 patients (~4-6% of all gastric cancer cases)
- This is the third approved indication for ORPATHYS in China; it is already on the NRDL (since March 2023) for prior lung cancer indication
- Drug is jointly developed with AstraZeneca, which commercializes it in China
Financial Impact
Expands the addressable patient population for ORPATHYS by adding ~18,000 incident MET-amplified GC/GEJ patients per year in China. Revenue contribution will depend on NRDL pricing, market penetration, and duration of therapy (median DoR 9.7 months). As the first selective MET inhibitor approved for this indication, near-term revenue upside is clear but not yet quantifiable from the filing alone.
Risk Factors
- Conditional approval may require confirmatory trial data; failure to meet post-marketing requirements could lead to label restriction
- MET amplification prevalence is only ~4-6% of gastric cancer, limiting absolute patient numbers
- Pricing and NRDL negotiation for this specific indication are unknown; reimbursement terms could constrain margins
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001648257-26-000047 |
| Document: hcm-20260702x6k.htm | 0001648257-26-000047 |
| Document: 0001648257-26-000047-index-headers.html | 0001648257-26-000047 |
| Document: 0001648257-26-000047-index.html | 0001648257-26-000047 |
| Document: 0001648257-26-000047.txt | 0001648257-26-000047 |
Track record
33 reports on HCM
7 of 8 bullish or bearish reports moved the stock their way by T+60. Best: +38.35% at T+60 after the Jun 25, 2026 report. 17 of 22 went positive at some point.
Filters
- Nov 15, 20261d ago Press Release Neutral 4/10 Entry $14.90 Now $14.73 −1.14% settles Feb 12
- Nov 5, 202611d ago 6-K Bullish 5/10 Entry $14.20 Now $14.73 +3.73% settles Feb 3
- Nov 2, 202614d ago 6-K Bullish 6/10 Entry $13.27 Now $14.73 +11.00% settles Jan 29
- Nov 2, 202615d ago Press Release Bullish 6/10 Entry $13.08 Now $14.73 +12.61% settles Feb 1
- Oct 29, 202618d ago 6-K Neutral 4/10 Entry $13.59 Now $14.73 +8.39% settles Jan 27
- Oct 27, 202620d ago 6-K Neutral 2/10 Entry $13.80 Now $14.73 +6.74% settles Jan 25
- Oct 26, 202621d ago 6-K Bullish 6/10 Entry $14.27 Now $14.73 +3.22% settles Jan 22
- Oct 26, 202621d ago Press Release Bullish 7/10 Entry $14.27 Now $14.73 +3.22% settles Jan 22
- Oct 26, 202622d ago Press Release Bullish 7/10 Entry $13.80 Now $14.73 +6.74% settles Jan 25
- Oct 21, 202626d ago 6-K Bullish 7/10 Entry $14.37 Now $14.73 +2.51% settles Jan 19
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers